US Patent

US10533032 — Crystalline form of benzylbenzene SGLT2 inhibitor

Method of Use · Assigned to THERACOS SUB LLC · Expires 2031-07-03 · 5y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects crystalline forms of a compound that inhibits sodium-dependent glucose cotransporter SGLT2, and methods of using it to treat diseases affected by SGLT or SGLT2 inhibition.

USPTO Abstract

Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

Drugs covered by this patent

Brenzavvy (BEXAGLIFLOZIN) · Theracosbio

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2214`	—	Brenzavvy

Patent Metadata

Patent number: US10533032
Jurisdiction: US
Classification: Method of Use
Expires: 2031-07-03
Drug substance claim: No
Drug product claim: No
Assignee: THERACOS SUB LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.